With Covid-19 Halting Clinical Trials, Wearables Could be Key — But Data ‘Wild West’ Gets in the Way Date Published: Aug 11, 2020 Article Before the COVID-19 pandemic, leveraging digital technologies in medical product development seemed impossible with the industry’s patient recruitment, timeline, and success rate struggles. However the global lockdown forced researchers to reconsider, forever changing how clinical trials are conducted. For the first time ever, pharmaceutical and technology companies collaborated to develop common study standards and protocols. But this is just the start. Find out why this collaboration needs to continue to improve clinical trials beyond the pandemic. Read More Share: LinkedInTweet Recommended Resources Article Optimal COA Measurement Strategy in Modern Oncology Trials The inclusion of patient-reported outcomes (PRO) data in oncology medication labeling in the U.S. has been comparatively limited. Recent FDA... Read Now Article Innovations in Clinical Neuroscience: Articles on Pediatric and Orphan Disease Clinical Research Dr. Joan Busner, Signant’s Clinical Vice President and in-house expert on pediatric and orphan disease clinical trials, recently co-authored three... Download Now Article Cariprazine Found to be Effective Adjunctive Treatment for Major Depressive Disorder Treating major depressive disorder can be challenging since many patients do not respond to initial antidepressant treatment, leading to continued... Read the Article